Targeted Inhibitors of EGFR: Structure, Biology, Biomarkers, and Clinical Applications
N Shaban, D Kamashev, A Emelianova, A Buzdin - Cells, 2023 - mdpi.com
Members of the EGFR family of tyrosine kinase receptors are major regulators of cellular
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …
proliferation, differentiation, and survival. In humans, abnormal activation of EGFR is …
Epidermal growth factor receptor inhibition in the management of squamous cell carcinoma of the lung
GD Goss, JN Spaans - The oncologist, 2016 - academic.oup.com
Molecular therapies targeting epidermal growth factor receptor (EGFR) have had a profound
impact on the management of advanced non-small cell lung cancer (NSCLC). EGFR …
impact on the management of advanced non-small cell lung cancer (NSCLC). EGFR …
Conformational insight on WT-and mutated-EGFR receptor activation and inhibition by epigallocatechin-3-gallate: Over a rational basis for the design of selective non …
C Minnelli, E Laudadio, G Mobbili… - International journal of …, 2020 - mdpi.com
Non-small cell lung cancer (NSCLC) represents a difficult condition to treat, due to
epidermal growth factor receptor (EGFR) kinase domain mutations, which lead to ligand …
epidermal growth factor receptor (EGFR) kinase domain mutations, which lead to ligand …
[PDF][PDF] Genome-scale signatures of gene interaction from compound screens predict clinical efficacy of targeted cancer therapies
Identifying reliable drug response biomarkers is a significant challenge in cancer research.
We present computational analysis of resistance (CARE), a computational method focused …
We present computational analysis of resistance (CARE), a computational method focused …
Computational insights into the potential of Withaferin-A, withanone and caffeic acid phenethyl ester for treatment of aberrant-EGFR driven lung cancers
The anticancer activities of Withaferin-A (Wi-A) and Withanone (Wi-N) from Ashwagandha
and Caffeic Acid Phenethyl Ester (CAPE) from honeybee propolis have been well …
and Caffeic Acid Phenethyl Ester (CAPE) from honeybee propolis have been well …
MicroRNA-16 Restores Sensitivity to Tyrosine Kinase Inhibitors and Outperforms MEK Inhibitors in KRAS-Mutated Non-Small Cell Lung Cancer
F Fanini, E Bandini, M Plousiou, S Carloni… - International journal of …, 2021 - mdpi.com
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer death
worldwide. Chemotherapy, the treatment of choice in non-operable cases, achieves a …
worldwide. Chemotherapy, the treatment of choice in non-operable cases, achieves a …
FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy
Á Quintanal-Villalonga, I Ferrer, E Guruceaga… - …, 2020 - thelancet.com
Background Fibroblast growth factor receptor (FGFR) 1 and FGFR4 have been associated
with tumorigenesis in a variety of tumour types. As a therapeutic approach, their inhibition …
with tumorigenesis in a variety of tumour types. As a therapeutic approach, their inhibition …
The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
DL Smith, J Acquaviva, M Sequeira, JP Jimenez… - Targeted Oncology, 2015 - Springer
Small molecule inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase
activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer …
activity, such as erlotinib and gefitinib, revolutionized therapy for non-small cell lung cancer …
Role of afatinib in the treatment of advanced lung squamous cell carcinoma
T Vavalà - Clinical Pharmacology: Advances and Applications, 2017 - Taylor & Francis
Lung cancer treatment has considerably changed over the last few years: the identification
of druggable oncogenic alterations and innovative immunotherapic approaches granted …
of druggable oncogenic alterations and innovative immunotherapic approaches granted …
[HTML][HTML] Biomarkers of erlotinib response in non-small cell lung cancer tumors that do not harbor the more common epidermal growth factor receptor mutations
BD López-Ayllón, J de Castro-Carpeño… - … Journal of Clinical …, 2015 - ncbi.nlm.nih.gov
Non-small cell lung cancer (NSCLC) represents approximately 85% of all lung cancers,
which are the leading cause of cancer-related deaths in the world. Tyrosine kinase inhibitors …
which are the leading cause of cancer-related deaths in the world. Tyrosine kinase inhibitors …